OBJECTIVES: To perform a patterns of care analysis for patients with prostate cancer and high-risk pathologic factors following radical prostatectomy with regards to adjuvant radiation. METHODS: A retrospective analysis was conducted using the Surveillance, Epidemiology and End Results (SEER) Program. We identified men from 2004 to 2005 with prostate adenocarcinoma (PA) who had undergone radical prostatectomy (RP) and were found to have extracapsular extension (ECE) with positive margins. RESULTS: We identified 1427 PA patients with ECE and positive margins after an RP. Most were clinically staged as T1 or T2 before surgery (95.8%). Using the D'Amico Risk Stratification, 52.0% were high-risk, 39.7% were intermediate-risk, and 8.3% were low-risk. Of these, 18.2% (260) received ART, whereas 81.8% (1167) did not. Those who received ART had worse prognostic factors, such as Gleason scores > 7 (38.5% vs 24.8%; P < .0001), prostate-specific antigen level > 10 (44.6% vs 35.2%; P = .0045), pathologically positive lymph nodes (11.5% vs 6.4%; P = .006), and D'Amico high-risk disease (66.8% vs 48.7%; P < .0001). The use of ART based on geographic region ranged from 8.3%-34.2%. CONCLUSIONS: Less than 20% of patients with pT3 disease and positive margins received ART in the study period just before the publication of randomized data demonstrating an improvement in biochemical failure with ART in this SEER retrospective analysis. This is the largest patterns of care analysis to date of ART in patients with margin-positive pT3 prostate adenocarcinoma. Published by Elsevier Inc.
OBJECTIVES: To perform a patterns of care analysis for patients with prostate cancer and high-risk pathologic factors following radical prostatectomy with regards to adjuvant radiation. METHODS: A retrospective analysis was conducted using the Surveillance, Epidemiology and End Results (SEER) Program. We identified men from 2004 to 2005 with prostate adenocarcinoma (PA) who had undergone radical prostatectomy (RP) and were found to have extracapsular extension (ECE) with positive margins. RESULTS: We identified 1427 PA patients with ECE and positive margins after an RP. Most were clinically staged as T1 or T2 before surgery (95.8%). Using the D'Amico Risk Stratification, 52.0% were high-risk, 39.7% were intermediate-risk, and 8.3% were low-risk. Of these, 18.2% (260) received ART, whereas 81.8% (1167) did not. Those who received ART had worse prognostic factors, such as Gleason scores > 7 (38.5% vs 24.8%; P < .0001), prostate-specific antigen level > 10 (44.6% vs 35.2%; P = .0045), pathologically positive lymph nodes (11.5% vs 6.4%; P = .006), and D'Amico high-risk disease (66.8% vs 48.7%; P < .0001). The use of ART based on geographic region ranged from 8.3%-34.2%. CONCLUSIONS: Less than 20% of patients with pT3 disease and positive margins received ART in the study period just before the publication of randomized data demonstrating an improvement in biochemical failure with ART in this SEER retrospective analysis. This is the largest patterns of care analysis to date of ART in patients with margin-positive pT3 prostate adenocarcinoma. Published by Elsevier Inc.
Authors: Robert B Den; Kasra Yousefi; Edouard J Trabulsi; Firas Abdollah; Voleak Choeurng; Felix Y Feng; Adam P Dicker; Costas D Lallas; Leonard G Gomella; Elai Davicioni; R Jeffrey Karnes Journal: J Clin Oncol Date: 2015-02-09 Impact factor: 44.544
Authors: T N Showalter; K A Foley; E Jutkowitz; C D Lallas; E J Trabulsi; L G Gomella; A P Dicker; L T Pizzi Journal: Ann Oncol Date: 2011-06-09 Impact factor: 32.976
Authors: Timothy N Showalter; Nitin Ohri; Kristopher G Teti; Kathleen A Foley; Scott W Keith; Edouard J Trabulsi; Costas D Lallas; Adam P Dicker; Jean Hoffman-Censits; Laura T Pizzi; Leonard G Gomella Journal: Int J Radiat Oncol Biol Phys Date: 2011-05-24 Impact factor: 7.038
Authors: Anusha Kalbasi; Samuel Swisher-McClure; Nandita Mitra; Robert Sunderland; Marc C Smaldone; Robert G Uzzo; Justin E Bekelman Journal: Cancer Date: 2014-06-10 Impact factor: 6.860
Authors: Kosj Yamoah; Curtiland Deville; Neha Vapiwala; Elaine Spangler; Charnita M Zeigler-Johnson; Bruce Malkowicz; David I Lee; Michael Kattan; Adam P Dicker; Timothy R Rebbeck Journal: Urol Oncol Date: 2014-10-07 Impact factor: 3.498
Authors: Marco Lupattelli; Matthew Alcusky; Cynthia Aristei; Rita Bellavita; Barbara A Jereczek-Fossa; John McAna; Timothy N Showalter; Vittorio Maio Journal: Br J Radiol Date: 2015-09-22 Impact factor: 3.039
Authors: Jennifer Mason Lobo; Adam P Dicker; Christine Buerki; Elai Daviconi; R Jeffrey Karnes; Robert B Jenkins; Nirav Patel; Robert B Den; Timothy N Showalter Journal: PLoS One Date: 2015-04-02 Impact factor: 3.240